S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
The "King Of Quants" sees 10X potential... (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
The gold catalyst we’ve waited for (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
The "King Of Quants" sees 10X potential... (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
The gold catalyst we’ve waited for (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
The "King Of Quants" sees 10X potential... (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
The gold catalyst we’ve waited for (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
The "King Of Quants" sees 10X potential... (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
The gold catalyst we’ve waited for (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
The gold catalyst we’ve waited for (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?

Globus Medical - GMED Stock Forecast, Price & News

$53.37
+0.23 (+0.43%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$52.98
$54.11
50-Day Range
$51.83
$79.63
52-Week Range
$50.92
$81.78
Volume
1.21 million shs
Average Volume
1.46 million shs
Market Capitalization
$5.35 billion
P/E Ratio
28.69
Dividend Yield
N/A
Price Target
$70.91

Globus Medical MarketRank™ Forecast

Analyst Rating
Hold
2.09 Rating Score
Upside/​Downside
32.9% Upside
$70.91 Price Target
Short Interest
Bearish
5.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.70mentions of Globus Medical in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$2.26 M Sold Last Quarter
Proj. Earnings Growth
10.00%
From $2.30 to $2.53 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.94 out of 5 stars

Medical Sector

34th out of 995 stocks

Surgical & Medical Instruments Industry

3rd out of 103 stocks


GMED stock logo

About Globus Medical (NYSE:GMED) Stock

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

GMED Stock News Headlines

Globus Medical (NYSE:GMED) Downgraded by StockNews.com
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Bear of the Day: NuVasive (NUVA)
RBC Capital Reaffirms Their Buy Rating on Globus Medical (GMED)
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Globus Medical (GMED) Tops Q4 Earnings Estimates
Globus Medical Earnings Preview
Globus Medical: Back Pains
GMED Tanks on NuVasive Deal
Globus Medical and NuVasive announce merger agreement
See More Headlines
Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

GMED Company Calendar

Last Earnings
2/21/2023
Today
3/27/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
37957720
Employees
2,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$70.91
High Stock Price Forecast
$78.00
Low Stock Price Forecast
$61.00
Forecasted Upside/Downside
+32.9%
Consensus Rating
Hold
Rating Score (0-4)
2.09
Research Coverage
11 Analysts

Profitability

Net Income
$190.17 million
Pretax Margin
23.76%

Debt

Sales & Book Value

Annual Sales
$759.12 million
Cash Flow
$2.86 per share
Book Value
$18.43 per share

Miscellaneous

Free Float
75,818,000
Market Cap
$5.35 billion
Optionable
Optionable
Beta
1.05

Key Executives

  • Daniel T. ScavillaDaniel T. Scavilla
    President, Chief Executive Officer & Director
  • Keith W. PfeilKeith W. Pfeil
    CFO, Chief Accounting Officer & Senior VP
  • Kelly G. HullerKelly G. Huller
    Secretary, Senior VP & General Counsel
  • Brian Kearns
    Senior Vice President-Business Development













GMED Stock - Frequently Asked Questions

Should I buy or sell Globus Medical stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 sell rating, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMED, but not buy additional shares or sell existing shares.
View GMED analyst ratings
or view top-rated stocks.

What is Globus Medical's stock price forecast for 2023?

11 Wall Street analysts have issued twelve-month price targets for Globus Medical's stock. Their GMED share price forecasts range from $61.00 to $78.00. On average, they expect the company's share price to reach $70.91 in the next twelve months. This suggests a possible upside of 32.9% from the stock's current price.
View analysts price targets for GMED
or view top-rated stocks among Wall Street analysts.

How have GMED shares performed in 2023?

Globus Medical's stock was trading at $74.27 at the beginning of the year. Since then, GMED shares have decreased by 28.1% and is now trading at $53.37.
View the best growth stocks for 2023 here
.

Are investors shorting Globus Medical?

Globus Medical saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 4,530,000 shares, an increase of 17.1% from the February 28th total of 3,870,000 shares. Based on an average trading volume of 1,330,000 shares, the short-interest ratio is presently 3.4 days. Approximately 5.9% of the company's shares are sold short.
View Globus Medical's Short Interest
.

When is Globus Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our GMED earnings forecast
.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) issued its quarterly earnings data on Tuesday, February, 21st. The medical device company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. The medical device company earned $274.50 million during the quarter, compared to the consensus estimate of $276.40 million. Globus Medical had a trailing twelve-month return on equity of 11.93% and a net margin of 18.59%. The business's quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.49 EPS.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical issued an update on its FY 2023 earnings guidance on Tuesday, February, 21st. The company provided earnings per share guidance of $2.30-$2.30 for the period, compared to the consensus estimate of $2.34. The company issued revenue guidance of $1.10 billion-$1.10 billion, compared to the consensus revenue estimate of $1.12 billion.

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include William Blair Investment Management LLC (2.32%), GW&K Investment Management LLC (1.71%), Geneva Capital Management LLC (1.43%), JPMorgan Chase & Co. (1.34%), Geode Capital Management LLC (1.20%) and Wells Fargo & Company MN (1.19%). Insiders that own company stock include Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends
.

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $53.37.

How much money does Globus Medical make?

Globus Medical (NYSE:GMED) has a market capitalization of $5.35 billion and generates $759.12 million in revenue each year. The medical device company earns $190.17 million in net income (profit) each year or $1.86 on an earnings per share basis.

How many employees does Globus Medical have?

The company employs 2,600 workers across the globe.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042.

This page (NYSE:GMED) was last updated on 3/28/2023 by MarketBeat.com Staff